The hard-fought battle over Medicare’s prescription drug benefit is over, but the long-term effects of the new law are still unclear. Exactly who will benefit and by how much? Is it a victory for big pharma? Initial reactions are not always correct, and this examination into the true implications for pharmaceutical markets looks at all the facts.
This market briefing from Kalorama describes and assesses the provisions of the “Medicare Prescription Drug, Improvement and Modernization Act of 2003” and predicts their potential impacts on the American pharmaceutical industry. Numerous tables and figures regarding the Medicare age population, it economics and healthcare expenditures, support conclusions regarding this controversial piece of legislation.